Ziprasidone Hydrochloride + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Conduct Disorder
Conditions
Conduct Disorder, Oppositional Defiant Disorder
Trial Timeline
Jul 1, 2006 → Jun 1, 2008
NCT ID
NCT00676429About Ziprasidone Hydrochloride + Placebo
Ziprasidone Hydrochloride + Placebo is a phase 2 stage product being developed by Pfizer for Conduct Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00676429. Target conditions include Conduct Disorder, Oppositional Defiant Disorder.
What happened to similar drugs?
2 of 2 similar drugs in Conduct Disorder were approved
Approved (2) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00835107 | Approved | Completed |
| NCT00676429 | Phase 2 | Completed |
Competing Products
5 competing products in Conduct Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Symbicort pMDI with spacer device + Symbicort pMDI without spacer device | AstraZeneca | Phase 1 | 29 |
| Oxcarbazepine | Novartis | Approved | 43 |
| Aripiprazole | Bristol Myers Squibb | Approved | 43 |
| AVT03 + Denosumab | Alvotech | Phase 1 | 23 |
| Custirsen + Placebo + Moxifloxacin | Achieve Life Sciences | Phase 1 | 19 |